C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024

This “C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Understanding

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by over-expression of C-Met tyrosine kinase receptor which is normally expressed by epithelial cells. C-Met stimulation induces phosphorylation of some specific tyrosine residues such as (Y1003-Y1313-Y1230/1234/1235-Y1349-Y1365) thereby activating multiple downstream signaling pathways including RAS/ERK, PI3K/AKT, and cSRC kinase pathways. Owing to SRC activation, C-Met is considered as an epithelial-mesenchymal transition promoter which induces high level of HGF (Hepatocyte growth factor) and intra-tumoral C-Met expression that have been associated with the biology and prognosis in NSCLC. NSCLC is predominantly of three types based on the morphology of cancerous cells and these are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Smoking, being exposed to radiations, asbestos, and various chemicals such as arsenic, chromium, and others are the major risk factors for non-small cell lung cancer.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape is provided which includes the disease overview and C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) treatment guidelines. The assessment part of the report embraces, in depth C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve C-Met Mutated Non-Small Cell Lung Cancer (NSCLC).

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs Chapters

This segment of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs

EGF-816 (Nazartinib): Novartis OncologyNovarti’s lead drug candidate, EGF-816 (Nazartinib), is small molecule in combination with INC280 is in development for the treatment of non-small cell lung cancer. Clinical trials data demonstrated that EGF-816 (Nazartinib) for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) has beneficial effects. The drug is a new molecule which is an epidermal growth factor receptor antagonist that blocks the function of protein EGFR.

APL 101 (Bozitinib): Appolomics Inc.Apollomics drug APL 101 (Bozitinib) is an orally administered small molecule currently being evaluated for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and has demonstrated good safety and efficacy profile in phase II trials. APL 101 (Bozitinib) is an anti-neoplastics which inhibits the C-met protein.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Therapeutic Assessment

This segment of the report provides insights about the different C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in C-Met Mutated Non-small Cell Lung Cancer (NSCLC)

There are approx. 5+ key companies which are developing the therapies for C-Met Mutated Non-small Cell Lung Cancer (NSCLC). The companies which have their C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drug candidates in the mid to advanced stage, i.e. phase III include, Novartis Oncology and others.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

C-Met Mutated Non-small Cell Lung Cancer (NSCLC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Report Insights

• C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs?
• How many C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Apollomics Inc.
• Abbvie
• Janssen Research and Development

Key Products

• EGF-816 (Nazartinib)
• APL 101 (Bozitinib)
• Telisotuzumab Vedotin
• JNJ-6118637

This product will be delivered within 2 business days.